Thomas graduated from the University of Mainz in Germany, where he finished his PhD thesis in the field of cytokine research in 2001. Thereafter, he joined Dyax in Liege/Belgium, focusing on high throughput re-formatting of phage library derived Fabs to IgG antibodies and mammalian expression vectors before he took a position at the University of Braunschweig in Germany in 2003. During three years in Braunschweig, he was leading a research team working mainly on expression systems for antibodies and antibody fusion proteins. He is still giving lectures as a guest lecturer there. In 2006, Thomas joined Novartis in Basel /Switzerland and since then has worked on different technology development/evaluation projects as well as on NBE projects. He was awarded Novartis Leading Scientist in 2009 for achievements in enhancing cell line development procedures. In 2011, he was appointed New Technology Network Leader and became responsible for coordinating and conducting evaluation studies of external technologies as well as internal technology development programs within the Integrated Biologics Profiling Unit. In 2013, he became head of a cell line development team with a focus on technology development and cell lines for non-standard antibody molecules.